Navigation Links
Replidyne Discontinues Phase III Trial
Date:4/23/2008

LOUISVILLE, Colo., April 23 /PRNewswire-FirstCall/ -- Replidyne, Inc. (Nasdaq: RDYN) announced today that it has discontinued enrollment in a placebo-controlled Phase III clinical trial testing faropenem medoxomil (faropenem) in patients with acute exacerbation of chronic bronchitis (AECB). Replidyne took this action to conserve its cash assets and support initiatives that include pursuing strategic transactions and maintaining its research programs.

The AECB study is one in a package of four clinical trials, including two in community-acquired pneumonia and one in acute bacterial sinusitis, recommended as a way forward by the U.S. Food and Drug Administration for a new drug application submission for faropenem to treat these three adult community respiratory tract infections. Replidyne has not initiated the other three trials, and consistent with prior guidance, further faropenem development will depend on Replidyne securing a partner for the program.

"In the interest of conserving our financial position, we have made a difficult decision to discontinue enrollment in this faropenem trial," said Kenneth J. Collins, Replidyne's President and CEO. "This decision reflects our sense of urgency and the belief that in today's environment available cash assets broaden the scope of potential partnering and strategic options."

As of March 31, 2008, Replidyne had cash assets of approximately $78 million.

About Replidyne, Inc.

Replidyne is a biopharmaceutical company focused on discovering, developing, in-licensing and commercializing innovative anti-infective products. Replidyne's most advanced product candidate, faropenem medoxomil, is a novel oral community antibiotic, expected to be appropriate for use as a fir
'/>"/>

SOURCE Replidyne, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Replidyne Provides Strategic Update
2. Replidyne to Participate on Anti-infective Panel at RBC Capital Markets Healthcare Conference
3. Replidynes Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile
4. Replidynes Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile
5. Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
6. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
7. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
8. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
9. Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
10. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
11. Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity in Metastatic Pancreatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015  Pomerantz LLP is investigating ... ("Vitae" or the "Company") (NASDAQ: VTAE ).  ... Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. ... certain of its officers and/or directors have violated Sections ... 1934.  On February 27, 2015, the ...
(Date:2/27/2015)... Securities lawyers at Dunnam & Dunnam ... (NASDAQ: SLXP ) in connection with a ... are encouraged to contact attorney Hamilton Lindley by ... upon the shareholder value of the transaction. Under terms ... $158.00 per share in cash. At least one analyst ...
(Date:2/27/2015)... 2015 Report Details   ... trends, R&D progress, and predicted revenues ,Where is the ... the commercial prospects for this market and related technologies? ... other trends to 2025, discussing data, opportunities and prospects. ... regenerative medicine : cell-based therapies that aim to ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8
... Pharmos Corporation (OTC-PINK: PARS) today reported financial results for ... These results are included in the Company,s Quarterly Report on ... Second Quarter Ended June 30, 2011The Company recorded ... for the second quarter 2011 compared to a net loss ...
... Md., Aug. 8, 2011 /PRNewswire-Asia/ -- Chindex International, Inc. ... company providing health care services in China through the operations ... hospitals and affiliated ambulatory clinics, today announced financial results for ... 30, 2011. Second Quarter 2011 ...
Cached Medicine Technology:Pharmos Corporation Reports 2011 Second Quarter Results 2Pharmos Corporation Reports 2011 Second Quarter Results 3Pharmos Corporation Reports 2011 Second Quarter Results 4Pharmos Corporation Reports 2011 Second Quarter Results 5Chindex International, Inc. Reports Financial Results for the Second Quarter and First Half of 2011 2Chindex International, Inc. Reports Financial Results for the Second Quarter and First Half of 2011 3Chindex International, Inc. Reports Financial Results for the Second Quarter and First Half of 2011 4Chindex International, Inc. Reports Financial Results for the Second Quarter and First Half of 2011 5Chindex International, Inc. Reports Financial Results for the Second Quarter and First Half of 2011 6Chindex International, Inc. Reports Financial Results for the Second Quarter and First Half of 2011 7Chindex International, Inc. Reports Financial Results for the Second Quarter and First Half of 2011 8Chindex International, Inc. Reports Financial Results for the Second Quarter and First Half of 2011 9Chindex International, Inc. Reports Financial Results for the Second Quarter and First Half of 2011 10Chindex International, Inc. Reports Financial Results for the Second Quarter and First Half of 2011 11
(Date:2/28/2015)... 2015 National Sales Solutions ... marketing and supply chain management for consumer packaged ... bringing its award winning solutions for thinning-damaged hair ... are specifically created to combat thinning-damaged hair. ... committed to marrying science with nature to create ...
(Date:2/28/2015)... Kaylie Corrigan, Outdoor Supervisor at ... and current student obtaining her Masters degree in social ... forum in psychoeducation on substance use for teens at ... part of her studies. , “Even though these students ... counseling at the high school and junior high school ...
(Date:2/28/2015)... 2015 The noted Toronto plastic surgeon ... was recently featured in the January/February 2015 issue of ... David Ellis was featured in an article entitled “Get ... enhancements that Kim Cattrall has possibly undergone to maintain ... is smooth without horizontal lines or frown line creases, ...
(Date:2/28/2015)... Plugin creators from Pixel Film Studios ... fully customizable transition pack made specifically for ... users total control over 30 transition presets built exclusively ... Film Studios. “TransFold Volume 2 gives endless possibilities to ... 2 from Pixel Film Studios brings back folding screen ...
(Date:2/28/2015)... 2015 1Heart Caregiver Services CEO ... brand at Houston Texas Franchise Expo South and ... its executive delegates headed by Vice-President of Operations ... Training Randolph Clarito. , Franchise Expo South, sponsored ... February 4-7 and featured Franchise brands of every ...
Breaking Medicine News(10 mins):Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3Health News:Staff at Arizona Drug Addiction Treatment Center Starts Teen Sobriety Support Group at Local High School 2Health News:Dr. David Ellis Featured In Elevate Magazine 2Health News:Announcing a New TransFold Transition Pack from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:1Heart Caregiver Services Showcases Emerging Brand at Franchise Expo South and IFA Annual Convention 2Health News:1Heart Caregiver Services Showcases Emerging Brand at Franchise Expo South and IFA Annual Convention 3
... CHICAGO, Feb. 26 A lawsuit was filed today ... boy who contracted salmonella poisoning,after eating at a Blueberry ... The child was hospitalized for three days as a ... the Cook County Department of Health,after the Communicable Disease ...
... Feb. 26 CVS Caremark Corporation (NYSE: ... Executive Vice President, Chief Financial Officer and Chief ... investors at the Raymond James Institutional Investors Conference ... to speak at approximately 8:05 a.m. EDT. ...
... Pharmaceutical Association (GPhA) today applauded President Obama,s budget ... biogenerics that will substantially reduce health care costs ... prices. The President,s budget proposal would ensure that ... model, by ensuring that brand companies cannot extend ...
... ATLANTA, Feb. 26, 2009 Arthritis affects more than ... be a substantial barrier to utilizing physical activity to ... Morbidity and Mortality Weekly Report ( MMWR ) ... and Prevention (CDC). According to the Arthritis Foundation, the ...
... in sunscreen, researchers say , , THURSDAY, Feb. 26 (HealthDay News) ... protection from skin cancer, and new research may explain why. ... mechanism by which caffeine is associated with decreased skin cancer," ... dermatology at the University of Washington in Seattle. , For ...
... Congress Must Reform Ineffective 33-year-old Chemicals Law, Expert Testifies ... the nation,s main chemicals law, the Toxic Substances Control ... ensure the safety of the tens of thousands of ... the conclusion of expert testimony provided at a ...
Cached Medicine News:Health News:CVS Caremark Corporation to Present at the Raymond James Institutional Investors Conference on March 10th 2Health News:GPhA Praises President Obama's Support for Safe and Affordable Biogenerics as Critical Solution to America's Ailing Health Care System 2Health News:Arthritis hinders physical activity for adults with heart disease 2Health News:Caffeine May Offer Some Skin Cancer Protection 2Health News:Caffeine May Offer Some Skin Cancer Protection 3Health News:Main U.S. Toxics Law Failing to Ensure Safety of Thousands of Chemicals 2Health News:Main U.S. Toxics Law Failing to Ensure Safety of Thousands of Chemicals 3
The AXIUS™ Blower/Mister provides controlled delivery of CO2 and saline to improve visibility during anastomosis....
The RX HERCULINK® PLUS Biliary Stent System is Guidant's high performance .014" guide wire compatible system. It is available in stent diameters of 4.0-6.5mm for the 12mm stent length and 4.0-7.0...
... Unique triaxial catheter design and ... deployment. Six proprietary radiopaque Nitinol markers ... of the stent enhance visibility. Corrugated ... strength, while the nested ring pattern ...
... left heart catheterization occurs when the initial ... sheath with an alternate curve while maintaining ... exchange has required a repeat septal puncture--complex ... overcome this problem with the unique PERRY ...
Medicine Products: